Novel Biodegradable Lipids for the Delivery of mRNA to Liver and Genome Editing in Lung Epithelia
Wednesday, July 16, 2025
2:54 PM – 3:05 PM EDT
Introduction: The success of mRNA-based Pfizer and Moderna COVID-19 vaccines highlighted the potential of RNA therapy. Here, we present our work on developing delivery systems to target other chronic diseases, including liver cancers and congenital lung conditions such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and alpha-1 antitrypsin (AAT) deficiency.
Learning Objectives:
At the completion of this activity, participants will know
Gain Insights into Cutting-Edge Research and Innovations
Enhance Professional Skills and Knowledge
Build Collaborative Networks and Explore Career Opportunities
